Factsheet as on May 31, 2025
 

Factsheet as on May 31, 2025

Nippon India Pharma Fund

Back
Back
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Sailesh Raj Bhan
Exit Load
Within 1 Month - 1%
Fund Size
Rs 8352 crs
Launch Date
June 05, 2004

Investment Objective

To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.


Market Cap Allocation



Scheme Performance

 1 Year2 Years3 Years5 Years
Scheme (%) 16.73 31.93 23.5622.02
Nifty 500 (%) 8.07 20.26 17.32 23.83
Returns are CAGR

Top 10 Holdings

Company Name% of Assets
Sun Pharmaceutical Industries Ltd. 12.6
Divi Laboratories Ltd. 9.5
Lupin Ltd. 5.8
Cipla Ltd. 5.6
Dr Reddys Laboratories Ltd. 5.5
Apollo Hospitals Enterprise Ltd. 5.3
Medplus Health Services Ltd. 4.2
Glaxo Smithkline Pharmaceuticals Ltd. 3.7
Vijaya Diagnostic Centre Ltd. 3.2
Narayana Hrudayalaya Ltd. 2.9

Year On Year Performance (Scheme V/S Nifty 500)


Ratios:
Standard Deviation    14.96
Information Ratio     0.14
Beta     0.74
Sharpe Ratio     0.30

Top 10 Sectoral Holdings (%)

SIP Returns


Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries

Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390

Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390